340B Legislative and Regulatory Update

The 340B Drug Pricing Program remains a lifeline for hospitals serving vulnerable communities—and it continues to face pressure from Congress, federal regulators and drug manufacturers. This session gave hospital finance leaders an update on recent legislative activity and regulatory developments affecting 340B, along with practical considerations for protecting program savings in the year ahead.